• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019.美国疫苗伤害赔偿计划(VICP)的绩效:1988-2019 年。
Vaccine. 2020 Feb 24;38(9):2136-2143. doi: 10.1016/j.vaccine.2020.01.042. Epub 2020 Jan 22.
2
An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches.利用疫苗贴剂改善疫苗的接种方式,为提高美国疫苗安全性而激励创新的机会。
Vaccine. 2020 May 22;38(25):4060-4065. doi: 10.1016/j.vaccine.2020.04.044. Epub 2020 Apr 21.
3
Update on the National Vaccine Injury Compensation Program.国家疫苗伤害赔偿计划最新情况
J Emerg Med. 2007 Aug;33(2):199-211. doi: 10.1016/j.jemermed.2007.01.001. Epub 2007 Jun 18.
4
National vaccine injury compensation program: calculation of average cost of a health insurance policy. Final rule.国家疫苗伤害赔偿计划:健康保险政策平均成本的计算。最终规则。
Fed Regist. 2007 Jul 5;72(128):36610-2.
5
National Vaccine Injury Compensation Program (VICP): effective date provisions of coverage of certain vaccines to the vaccine injury table--HRSA. Final rule.国家疫苗伤害赔偿计划(VICP):某些疫苗纳入疫苗伤害表的生效日期规定——卫生资源与服务管理局。最终规则。
Fed Regist. 1998 May 11;63(90):25777-8.
6
Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010-2016.疫苗接种相关肩部损伤(SIRVA):请愿人向 2010-2016 年国家疫苗伤害赔偿计划提出索赔。
Vaccine. 2020 Jan 29;38(5):1076-1083. doi: 10.1016/j.vaccine.2019.11.032. Epub 2019 Nov 23.
7
Do vaccines cause epilepsy? Review of cases in the National Vaccine Injury Compensation Program.疫苗会引发癫痫吗?对国家疫苗伤害赔偿计划中的案例回顾。
Epilepsia. 2024 Feb;65(2):293-321. doi: 10.1111/epi.17794. Epub 2023 Dec 28.
8
Economic and immunisation safety surveillance characteristics of countries implementing no-fault compensation programmes for vaccine injuries.实施疫苗伤害无过错赔偿计划的国家的经济和免疫安全监测特征。
Vaccine. 2019 Jul 18;37(31):4370-4375. doi: 10.1016/j.vaccine.2019.06.018. Epub 2019 Jun 15.
9
The National Vaccine Injury Compensation Program.国家疫苗伤害赔偿计划。
Pediatrics. 2011 May;127 Suppl 1:S74-7. doi: 10.1542/peds.2010-1722K. Epub 2011 Apr 18.
10
National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table. Final rule.国家疫苗伤害赔偿计划:疫苗伤害表修订。最终规则。
Fed Regist. 2017 Jan 19;82(12):6294-305.

引用本文的文献

1
Policy strategies for inclusion of pregnant and lactating women in vaccine research.将孕妇和哺乳期妇女纳入疫苗研究的政策策略。
Health Aff Sch. 2025 Feb 19;3(3):qxaf035. doi: 10.1093/haschl/qxaf035. eCollection 2025 Mar.
2
Spectrum and Incidence of Adverse Reactions Post Immunization in the Taiwanese Population (2014-2019): An Analysis Using the National Vaccine Injury Compensation Program.台湾地区人群(2014 - 2019年)免疫接种后不良反应的谱和发生率:一项使用国家疫苗伤害补偿计划的分析
Vaccines (Basel). 2024 Oct 3;12(10):1133. doi: 10.3390/vaccines12101133.
3
Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.支持全球消灭脊髓灰质炎的脊髓灰质炎病毒传播综述与经济建模:2020 - 2024年
Pathogens. 2024 May 22;13(6):435. doi: 10.3390/pathogens13060435.
4
Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.不同脊髓灰质炎疫苗选择在应对美国和其他仅在常规免疫中使用灭活脊髓灰质炎疫苗(IPV)的国家的脊髓灰质炎疫情中的权衡。
Vaccine. 2024 Feb 6;42(4):819-827. doi: 10.1016/j.vaccine.2023.12.081. Epub 2024 Jan 12.
5
A review of China's compensation program for adverse reactions following immunization.中国预防接种不良反应补偿方案综述。
Front Public Health. 2023 Aug 7;11:1211976. doi: 10.3389/fpubh.2023.1211976. eCollection 2023.
6
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.美国口服脊髓灰质炎疫苗预防 COVID-19 的健康经济分析。
Risk Anal. 2021 Feb;41(2):376-386. doi: 10.1111/risa.13614. Epub 2020 Oct 20.
7
An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches.利用疫苗贴剂改善疫苗的接种方式,为提高美国疫苗安全性而激励创新的机会。
Vaccine. 2020 May 22;38(25):4060-4065. doi: 10.1016/j.vaccine.2020.04.044. Epub 2020 Apr 21.

本文引用的文献

1
Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010-2016.疫苗接种相关肩部损伤(SIRVA):请愿人向 2010-2016 年国家疫苗伤害赔偿计划提出索赔。
Vaccine. 2020 Jan 29;38(5):1076-1083. doi: 10.1016/j.vaccine.2019.11.032. Epub 2019 Nov 23.
2
The National Vaccine Injury Compensation Program: Striking a Balance Between Individual Rights and Community Benefit.国家疫苗伤害赔偿计划:在个人权利与社区利益之间寻求平衡。
JAMA. 2019 Jan 29;321(4):343-344. doi: 10.1001/jama.2018.20421.
3
Economic evaluation of the routine childhood immunization program in the United States, 2009.2009 年美国常规儿童免疫规划的经济学评价。
Pediatrics. 2014 Apr;133(4):577-85. doi: 10.1542/peds.2013-0698. Epub 2014 Mar 3.
4
The National Vaccine Injury Compensation Program.国家疫苗伤害赔偿计划。
Pediatrics. 2011 May;127 Suppl 1:S74-7. doi: 10.1542/peds.2010-1722K. Epub 2011 Apr 18.
5
Shoulder injury related to vaccine administration (SIRVA).疫苗接种相关肩部损伤(SIRVA)。
Vaccine. 2010 Nov 29;28(51):8049-52. doi: 10.1016/j.vaccine.2010.10.005. Epub 2010 Oct 16.
6
Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.美国疫苗可预防疾病的发病率和死亡率的历史比较。
JAMA. 2007 Nov 14;298(18):2155-63. doi: 10.1001/jama.298.18.2155.
7
Vaccine injury compensation programs worldwide.全球疫苗伤害赔偿计划。
Vaccine. 1999 Oct 29;17 Suppl 3:S25-35. doi: 10.1016/s0264-410x(99)00291-1.
8
United States vaccine research: a delicate fabric of public and private collaboration. National Vaccine Advisory Committee.美国疫苗研究:公共与私人合作的微妙架构。国家疫苗咨询委员会。
Pediatrics. 1997 Dec;100(6):1015-20. doi: 10.1542/peds.100.6.1015.

美国疫苗伤害赔偿计划(VICP)的绩效:1988-2019 年。

Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019.

机构信息

Kid Risk, Inc., Orlando, FL, USA.

Emory University, Atlanta, GA, USA.

出版信息

Vaccine. 2020 Feb 24;38(9):2136-2143. doi: 10.1016/j.vaccine.2020.01.042. Epub 2020 Jan 22.

DOI:10.1016/j.vaccine.2020.01.042
PMID:31982259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7853082/
Abstract

The United States (US) highly values the individual and societal benefits of vaccination and invests significantly in vaccine development and use as part of its national vaccine enterprise. In 1986, recognizing the small, but non-zero risks associated with vaccines, the US created a mechanism to collect excise taxes on each dose of vaccine to fund a national Vaccine Injury Compensation Program (VICP). The VICP includes a system for those claiming serious injuries from vaccines to seek compensation, and a process to pay individuals with legitimate claims and their legal counsel. Given the maturity of the VICP, we review experience with the vaccines and injuries covered, claims, and economics of the fund. Our review shows the excellent safety track record of vaccines, provides some evidence of injuries related specifically to vaccine delivery, and discusses the financial health of the fund.

摘要

美国高度重视疫苗接种给个人和社会带来的效益,并将大量资源投入到疫苗的开发和使用中,以此作为其国家疫苗事业的一部分。1986 年,美国认识到疫苗存在着微小但并非为零的风险,因此建立了一种机制,对每剂疫苗征收消费税,为国家疫苗损伤赔偿计划(VICP)提供资金。VICP 包括一个针对因疫苗而遭受严重伤害的人寻求赔偿的系统,以及一个向合法索赔者及其法律顾问支付款项的流程。鉴于 VICP 的成熟度,我们回顾了涵盖的疫苗和伤害、索赔以及基金的经济学经验。我们的审查结果表明,疫苗具有出色的安全记录,提供了一些与疫苗接种方式相关的伤害证据,并讨论了基金的财务健康状况。